Mechanisms and clinical relevance of androgens and androgen receptor actions

Chang Gung Medical Journal

Volumn 26, Issue 6, 2003, Pages 388-402

  Kang, Hong Yo ^a,b   Tsai, Meng Yin ^b   Chang, Chawnshang ^b   Huang, Ko En ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Androgen; Androgen receptor; Co regulators

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; DNA; ESTROGEN; FINASTERIDE; FLUTAMIDE; HYDROXYFLUTAMIDE; LIGAND; METRIBOLONE; TESTOSTERONE; TRANSCRIPTION FACTOR;

AGING; ANDROGEN INSENSITIVITY SYNDROME; BINDING AFFINITY; DNA BINDING; HORMONE RECEPTOR INTERACTION; HUMAN; LIGAND BINDING; MALE INFERTILITY; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SPERMATOGENESIS; TRANSCRIPTION REGULATION; BONE; MALE; PHYSIOLOGY; PROSTATE TUMOR; SEX DIFFERENTIATION;

ANDROGENS; BONE AND BONES; HUMANS; INFERTILITY, MALE; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SEX DIFFERENTIATION;

EID: 0142122829     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Bruchovsky N, Wilson JD. The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968;243:2012-21.
2. Imperato-McGinley J, Peterson RE, Gautier T, Sturla E. Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5alpha-reductase deficiency. N Engl J Med 1979;300:1233-7.
3. Peterson RE, Imperato-McGinley J, Gautier T, Sturla E. Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency. Am J Med 1977;62:170-91.
4. Chang CS, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988;240:324-6.
5. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988;240:327-30.
6. Yeh S, Tsai MY, Xu Q, Mu XM, Lardy H, Huang KE, Lin H, Yeh SD, Altuwaijri S, Zhou X, Xing L, Boyce BF. Hung MC, Zhang S, Gan L, Chang C. Generation and characterization of androgen receptor knockout (ARKO) mice: An in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A 2002.
7. Deslypere JP, Young M, Wilson JD, McPhaul MJ. Estosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 1992;88:15-22.
8. Kang HY, Yeh S, Fujimoto N, Chang C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 1999;274:8570-6.
9. Imperato-McGinley J, Sanchez RS, Spencer JR, Yee B, Vaughan ED. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies. Endocrinology 1992;131:1149-56.
10. Kumar N, Didolkar AK, Monder C, Bardin CW, Sundaram K. The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 1992;130:3677-83.
11. Sundaram K, Kumar N, Monder C, Bardin CW. Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens. J Steroid Biochem Mol Biol 1995;53:253-7.
12. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-44.
13. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
14. Giguere V. Orphan nuclear receptors: from gene to function. Endocr Rev 1999;20:689-725.
15. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, Chambon P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 1989;59:477-87.
16. Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 1999;19:8383-92.
17. Bocquel MT, Kumar V, Stricker C, Chambon P, Gronemeyer H. The contribution of the N- and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific. Nucleic Acids Res 1989;17:2581-95.
18. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 1994;264:1455-8.
19. Robyr D, Wolffe AP, Wahli W. Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol Endocrinol 2000;14:329-47.
20. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002;23:175-200.
21. Lemon B, Tjian R. Orchestrated response: a symphony of transcription factors for gene control. Genes Dev 2000;14:2551-69.
22. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 1997;389:194-8.
23. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996;87:953-9.
24. Fujimoto N, Mizokami A, Harada S, Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology 2001;58:289-94.
25. Ozanne DM, Brady ME, Cook S, Gaughan L, Neal DE, Robson CN. Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. Mol Endocrinol 2000;14:1618-26.
26. Heinlein CA, Chang C. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 2002;16:2181-7.
27. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. Embo J 2000;19:5406-17.
28. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001;104:719-30.
29. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP. Progesterone receptor contains a proline- rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 2001;8:269-80.
30. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997;13:513-609.
31. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000;100:293-6.
32. Konoplya EF, Popoff EH. Identification of the classical androgen receptor in male rat liver and prostate cell plasma membranes. Int J Biochem 1992;24:1979-83.
33. Benten WP, Lieberherr M, Giese G, Wrehlke C, Stamm O, Sekeris CE, Mossmann H, Wunderlich F. Functional testosterone receptors in plasma membranes of T cells. Faseb J 1999;13:123-33.
34. Gerdes D, Wehling M, Leube B, Falkenstein E. Cloning and tissue expression of two putative steroid membrane receptors. Biol Chem 1998;379:907-11.
35. Bernauer S, Wehling M, Gerdes D, Falkenstein E. The human membrane progesterone receptor gene: genomic structure and promoter analysis. DNA Seq 2001;12:13-25.
36. Luzardo OP, Machin RP, Diaz-Chico BN, Fernandez L. Photoaffinity labeling identification of a specific binding protein for the anabolic steroids stanozolol and danazol: an oligomeric protein regulated by age, pituitary hormones, and ethinyl estradiol. Endocrinology 2000;141:3377-87.
37. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31, 1.
38. Cooke PS, Young P, Cunha GR. Androgen receptor expression in developing male reproductive organs. Endocrinology 1991;128:2867-73.
39. Huggins CB. Commentary on the treatment of prostate cancer. J Urol 1969;102:119-20.
40. Stearns ME, McGarvey T. Prostate cancer: therapeutic, diagnostic, and basic studies. Lab Invest 1992;67:540-52.
41. Bentel JM, Tilley WD. Androgen receptors in prostate cancer. J Endocrinol 1996;151:1-11.
42. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y. DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL, Lamb DJ. Androgen receptor mutations in prostate cancer. Cancer Res 2000;60:944-9.
43. Wilson CM, McPhaul MJ. A and B forms of the androgen receptor are expressed in a variety of human tissues. Mol Cell Endocrinol 1996;120:51-7.
44. Sinclair AH, Berta P, Palmer MS, Hawkins JR, Griffiths BL, Smith MJ, Foster JW, Frischauf AM, Lovell-Badge R, Goodfellow PN. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature 1990;346:240-4.
45. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 1995;16:271-321.
46. Wilson JD, George FW, Griffin JE. The hormonal control of sexual development. Science 1981;211:1278-84.
47. Roberts KP, Zirkin BR. Androgen regulation of spermatogenesis in the rat. Ann N Y Acad Sci 1991;637:90-106.
48. Sar M, Lubahn DB, French FS, Wilson EM. Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology 1990;127:3180-6.
49. Takeda H, Chodak G, Mutchnik S, Nakamoto T, Chang C. Immunohistochemical localization of androgen receptors with mono- and polyclonal antibodies to androgen receptor. J Endocrinol 1990;126:17-25.
50. Shan LX, Zhu LJ, Bardin CW, Hardy MP. Quantitative analysis of androgen receptor messenger ribonucleic acid in developing Leydig cells and Sertoli cells by in situ hybridization. Endocrinology 1995;136:3856-62.
51. Shan LX, Bardin CW, Hardy MP. Immunohistochemical analysis of androgen effects on androgen receptor expression in developing Leydig and Sertoli cells. Endocrinology 1997;138:1259-66.
52. Abdelmassih R, Dhont M, Comhaire F. Pilot study with 120 mg Andriol treatment for couples with a low fertilization rate during in-vitro fertilization. Hum Reprod 1992;7:267-8.
53. Gerris J, Comhaire F, Hellemans P, Peeters K, Schoonjans F. Placebo-controlled trial of high-dose Mesterolone treatment of idiopathic male infertility. Fertil Steril 1991;55:603-7.
54. Schill WB. Survey of medical therapy in andrology. Int J Androl 1995;18 Suppl 2:56-62.
55. Aiman J, Griffin JE. The frequency of androgen receptor deficiency in infertile men. J Clin Endocrinol Metab 1982;54:725-32.
56. Morrow AF, Gyorki S, Warne GL, Burger HG, Bangah ML, Outch KH, Mirovics A, Baker HW. Variable androgen receptor levels in infertile men. J Clin Endocrinol Metab 1987;64:1115-21.
57. Lim J, Ghadessy FJ, Yong EL. A novel splice site mutation in the androgen receptor gene results in exon skipping and a non-functional truncated protein. Mol Cell Endocrinol 1997;131:205-10.
58. Yong EL, Ghadessy F, Wang Q, Mifsud A, Ng SC. Androgen receptor transactivation domain and control of spermatogenesis. Rev Reprod 1998;3:141-4.
59. Wang Q, Ghadessy FJ, Trounson A, de Kretser D, McLachlan R, Ng SC, Yong EL. Azoospermia associated with a mutation in the ligand-binding domain of an androgen receptor displaying normal ligand binding, but defective trans-activation. J Clin Endocrinol Metab 1998;83:4303-9.
60. Hiort O, Holterhus PM, Horter T, Schulze W, Kremke B, Bals-Pratsch M, Sinnecker GH, Kruse K. Significance of mutations in the androgen receptor gene in males with idiopathic infertility. J Clin Endocrinol Metab 2000;85:2810-5.
61. Hiort O. Neonatal endocrinology of abnormal male sexual differentiation: molecular aspects. Horm Res 2000;53 Suppl 1:38-41.
62. Imperato-McGinley J, Peterson RE, Gautier T, Cooper G, Danner R, Arthur A, Morris PL, Sweeney WJ, Shackleton C. Hormonal evaluation of a large kindred with complete androgen insensitivity: evidence for secondary 5 alpha- reductase deficiency. J Clin Endocrinol Metab 1982;54:931-41.
63. Nitsche EM, Hiort O. The molecular basis of androgen insensitivity. Horm Res 2000;54:327-33.
64. McPhaul MJ. Molecular defects of the androgen receptor. Recent Prog Horm Res 2002;57:181-94.
65. Mongan NP, Jaaskelainen J, Green K, Schwabe JW, Shimura N, Dattani M, Hughes IA. Two de novo mutations in the AR gene cause the complete androgen insensitivity syndrome in a pair of monozygotic twins. J Clin Endocrinol Metab 2002;87:1057-61.
66. Hellwinkel OJ, Bull K, Holterhus PM, Homburg N, Struve D, Hiort O. Complete androgen insensitivity caused by a splice donor site mutation in intron 2 of the human androgen receptor gene resulting in an exon 2-lacking transcript with premature stop-codon and reduced expression. J Steroid Biochem Mol Biol 1999;68:1-9.
67. Hellwinkel OJ, Holterhus PM, Struve D, Marschke C, Homburg N, Hiort O. A unique exonic splicing mutation in the human androgen receptor gene indicates a physiologic relevance of regular androgen receptor transcript variants. J Clin Endocrinol Metab 2001;86:2569-75.
68. Chu J, Zhang R, Zhao Z, Zou W, Han Y, Qi Q, Zhang H, Wang JC, Tao S, Liu X, Luo Z. Male fertility is compatible with an Arg (840) Cys substitution in the AR in a large Chinese family affected with divergent phenotypes of AR insensitivity syndrome. J Clin Endocrinol Metab 2002;87:347-51.
69. Adachi M, Takayanagi R, Tomura A, Imasaki K, Kato S, Goto K, Yanase T, Ikuyama S, Nawata H. Androgen-insensitivity syndrome as a possible coactivator disease. N Engl J Med 2000;343:856-62.
70. Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab 1997;82:3777-82.
71. Hiort O, Sinnecker GH, Holterhus PM, Nitsche EM, Kruse K. The clinical and molecular spectrum of androgen insensitivity syndromes. Am J Med Genet 1996;63:218-22.
72. MacLean HE, Warne GL, Zajac JD. Spinal and bulbar muscular atrophy: androgen receptor dysfunction caused by a trinucleotide repeat expansion. J Neurol Sci 1996;135:149-57.
73. Dowsing AT, Yong EL, Clark M, McLachlan RI, de Kretser DM, Trounson AO. Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene. Lancet 1999;354:640-3.
74. Lim J, Ghadessy FJ, Abdullah AA, Pinsky L, Trifiro M, Yong EL. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2). Mol Endocrinol 2000;14:1187-97.
75. Ghadessy FJ, Lim J, Abdullah AA, Panet-Raymond V, Choo CK, Lumbroso R, Tut TG, Gottlieb B, Pinsky L, Trifiro MA, Yong EL. Oligospermic infertility associated with an androgen receptor mutation that disrupts interdomain and coactivator (TIF2) interactions. J Clin Invest 1999;103:1517-25.
76. Levine DA, Boyd J. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. Cancer Res 2001;61:908-11.
77. Silva EG, Tornos C, Fritsche HA, Jr., el-Naggar A, Gray K, Ordonez NG, Luna M, Gershenson D. The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Mod Pathol 1997;10:879-83.
78. Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, Comstock GW. Serum gonadotropins and steroid hormones and the development of ovarian cancer. Jama 1995;274:1926-30.
79. Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC, van der Kwast TH. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol 1993;24:90-5.
80. Slotman BJ, Rao BR. Response to inhibition of androgen action of human ovarian cancer cells in vitro. Cancer Lett 1989;45:213-20.
81. Weil SJ, Vendola K, Zhou J, Adesanya OO, Wang J, Okafor J, Bondy CA. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 1998;83:2479-85.
82. Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998;101:2622-9.
83. Shaw PA, Rittenberg PV, Brown TJ. Activation of androgen receptor-associated protein 70 (ARA70) mRNA expression in ovarian cancer. Gynecol Oncol 2001;80:132-8.
84. Lea OA, Kvinnsland S, Thorsen T. Improved measurement of androgen receptors in human breast cancer. Cancer Res 1989;49:7162-7.
85. Bieche I, Parfait B, Tozlu S, Lidereau R, Vidaud M. Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene. Carcinogenesis 2001;22:1521-6.
86. Kollara A, Kahn HJ, Marks A, Brown TJ. Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers. Breast Cancer Res Treat 2001;67:245-53.
87. Gordon GB, Bush TL, Helzlsouer KJ, Miller SR, Comstock GW. Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. Cancer Res 1990;50:3859-62.
88. Giguere Y, Dewailly E, Brisson J, Ayotte P, Laflamme N, Demers A, Forest VI, Dodin S, Robert J, Rousseau F. Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. Cancer Res 2001;61:5869-74.
89. Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999;64:1371-7.
90. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C. Weger MA, Horsfall DJ, Tilley WD. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995;52:459-67.
91. Yeh S, Hu YC, Rahman M, Lin HK. Hsu CL, Ting HJ, Kang HY. Chang C. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Natl Acad Sci U S A 2000;97:11256-61.
92. Lapointe J, Fournier A, Richard V, Labrie C. Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells. Endocrinology 1999;140:416-21.
93. Finkelstein JS, Klibanski A, Neer RM, Doppelt SH, Rosenthal DI, Segre GV, Crowley WF. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989;69:776-83.
94. Dixon JE, Rodin A, Murby B, Chapman MG, Fogelman I. Bone mass in hirsute women with androgen excess. Clin Endocrinol (Oxf) 1989;30:271-7.
95. Johansen JS, Hassager C, Podenphant J, Riis BJ, Hartwell D, Thomsen K, Christiansen C. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate? Bone Miner 1989;6:77-86.
96. Vanderschueren D, Bouillon R. Androgens and bone. Calcif Tissue Int 1995;56:341-6.
97. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689-98.
98. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams T, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056-61.
99. Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahn DB, French FS, Riggs BL, Spelsberg TC. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A 1989;86:854-7.
100. Orwoll ES, Stribrska L, Ramsey EE, Keenan EJ. Androgen receptors in osteoblast-like cell lines. Calcif Tissue Int 1991;49:183-7.
101. Kasperk CH, Faehling K, Borcsok I, Ziegler R. Effects of androgens on subpopulations of the human osteosarcoma cell line SaOS2. Calcif Tissue Int 1996;58:376-82.
102. Nordin BE, Robertson A, Seamark RF, Bridges A, Philcox JC, Need AG, Horowitz M, Morris HA. The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women. J Clin Endocrinol Metab 1985;60:651-7.
103. Soule SG, Conway G, Prelevic GM, Prentice M, Ginsburg J, Jacobs HS. Osteopenia as a feature of the androgen insensitivity syndrome. Clin Endocrinol (Oxf) 1995;43:671-5.
104. Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE. The localization of androgen receptors in human bone. J Clin Endocrinol Metab 1997;82:3493-7.
105. Pederson L, Kremer M, Judd J. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci U S A 1999;96:505-10.
106. Notelovitz M. Effects of estrogen/androgen therapy on bone mineral density parameters. J Reprod Med 2001;46:325-31.
107. Castelo-Branco C, Vicente JJ, Figueras F. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000;34:161-8.
108. Kasperk CH, Wergedal JE, Farley JR, Linkhart TA, Turner RT, Baylink DJ. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989;124:1576-8.
109. Goulding A, Gold E. Flutamide-mediated androgen blockade evokes osteopenia in the female rat. J Bone Miner Res 1993;8:763-9.
110. Lea CK, Flanagan AM. Physiological plasma levels of androgens reduce bone loss in the ovariectomized rat. Am J Physiol 1998;274:E328-35.
111. Rosen HN, Tollin S, Balena R, Middlebrooks VL, Moses AC, Yamamoto M, Zeind AJ, Greenspan SL. Bone density is normal in male rats treated with finasteride. Endocrinology 1995;136:1381-7.
112. Matzkin H, Chen J, Weisman Y, Goldray D, Pappas F, Jaccard N, Braf Z. Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism. Clin Endocrinol (Oxf) 1992;37:432-6.
113. Centrella M, Horowitz MC, Wozney JM, McCarthy TL. Transforming growth factor-beta gene family members and bone. Endocr Rev 1994;15:27-39.
114. Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, Chang C. From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc Natl Acad Sci U S A 2001;98:3018-23.
115. Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM, Shevde NK, Pike JW. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 2001;142:3800-8.
116. Chen Q, Kaji H, Sugimoto T, Chihara K. Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor. FEBS Lett 2001;491:91-3.